

JHVS2022 Global Pitch 登壇企業

- [Braizon Therapeutics, Inc.](#) | 株式会社ブレイゾン・セラピューティクス

Providing pharma partners with Brain Access®, delivery technology that is key to conquering neurological diseases.

Braizon's platform provides a scalable solution to a major pain point in the pharma industry, getting drugs safely into the brain. Synthetic polymer nanoparticles encapsulate the therapeutic compound and target a regulatorily approved route to non-invasively enter the brain. Licensing partnerships support early revenue with long term growth supplied by milestone fees and sales royalties, expanding with replication across the customer base.

- [Celaid Therapeutics Inc.](#) | セレイドセラピューティクス株式会社

Providing a New Foundation for Curing Blood Disorders

Celaid has developed novel technology for ex vivo expansion of hematopoietic stem cells (HSCs) with the potential to transform the area of hematology. By replacing the current HSC transplantation standard of care, we hold the potential to cure leukemia and restore the quality of life for patients worldwide. Celaid's therapeutic development is advancing in the US and will be targeting FDA approval.

- [FunPep Co., Ltd.](#) | 株式会社ファンペップ

FunPep conducts R&D of antibody-inducing peptides using the platform technology for therapeutic vaccine designed.

FunPep Co., Ltd. is a biotechnology venture company focused on the development of functional peptides derived from the platform technology from the Graduate School of Medicine, Osaka University. FunPep's strength is that we possess the drug discovery platform technology for antibody-inducing peptides. Antibody-inducing peptides are functional peptides that produce antibodies which exhibit inhibitory activity against disease-causing proteins. Antibody-inducing peptides are a type of vaccine that utilizes the immune system and consists of a "B cell epitope" to identify the target molecule and a "helper T cell epitope" (AJP001) to induce an immune response. FunPep has been conducting research and development of antibody-inducing peptides using AJP001, with our lead product FPP003 in a Phase I/IIa clinical trial for psoriasis.

- [INOPASE Inc.](#) | 株式会社 INOPASE

Wireless powered closed-loop implantable neuromodulation device for treatment of overactive bladder and epilepsy

Neuromodulation is a clinically proven treatment for multiple chronic diseases by delivering electrical stimulation to various nerves. As the current neuromodulation can only deliver the pre-setting constant stimulation, INOPASE develops a closed-loop neuromodulation with a combination of nerve sensing and stimulation, aiming at the individual treatment. The company starts the neuromodulation development for treatment of overactive bladder and epilepsy.

- [Kidswell Bio Corporation](#) | キッズウェル・バイオ株式会社

SHED master cell bank for cell therapy and exploration of engineered SHED for enhanced efficacy

Kidswell Bio Corporation has confirmed the efficacy of SHED in animal models of neurological disorders and bone regeneration. We released S-QuatreSM, a one-stop service to provide highly reliable and GMP-compliant allogenic SHED as an intermediate product for cell therapy. We are initiating research activities to combine technologies from bio ventures/academia with our SHED for enhanced efficacy.

- [VCCT Inc.](#) | 株式会社 VC Cell Therapy

VC Cell Therapy: developing iPSC-based regenerative cell therapy for retinal degeneration

VC Cell Therapy is a clinical-stage biotech company developing two assets for retinal degeneration - allogenic HLA-KO RPE cells and photoreceptors. Past clinical research has shown safety of our products and indicated efficacy, in part, due to the unique drug formulation and automated manufacturing. The products will become available in Japan from as soon as 2023 as experimental therapy.